
Sign up to save your podcasts
Or


Kian Sadeghi, founder and CEO of Nucleus Genomics, joins the show to unpack the fall of 23andMe and what its $256M acquisition by Regeneron means for the future of consumer DNA testing.
We talk about what 23andMe got wrong—from its business model to its reliance on outdated genotyping tech—and how a new generation of genomic startups like Nucleus are taking a different approach: full genome sequencing, HIPAA compliance, and consumer empowerment.
We also covered Klarna’s rising credit losses, JPMorgan’s AI-driven hiring slowdown, Waymo’s expansion into San Jose, and Zoox’s new test market in Atlanta.
By Eric Tarczynski5
1616 ratings
Kian Sadeghi, founder and CEO of Nucleus Genomics, joins the show to unpack the fall of 23andMe and what its $256M acquisition by Regeneron means for the future of consumer DNA testing.
We talk about what 23andMe got wrong—from its business model to its reliance on outdated genotyping tech—and how a new generation of genomic startups like Nucleus are taking a different approach: full genome sequencing, HIPAA compliance, and consumer empowerment.
We also covered Klarna’s rising credit losses, JPMorgan’s AI-driven hiring slowdown, Waymo’s expansion into San Jose, and Zoox’s new test market in Atlanta.

16,155 Listeners

1,281 Listeners

535 Listeners

4,338 Listeners

1,937 Listeners

1,096 Listeners

2,360 Listeners

112,105 Listeners

6,062 Listeners

2,644 Listeners

10,026 Listeners

518 Listeners

29,214 Listeners

987 Listeners

474 Listeners